SCHEMBL3482659

SCHEMBL3482659

O=C(O)C1C(C(=O)O)C(c2ccccc2)C1c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 4/20 0.61
▸ HDAC3 O15379 1/20 0.61
▸ HDAC7 Q8WUI4 1/20 0.61
▸ HDAC8 Q9BY41 1/20 0.61
▸ HDAC6 Q9UBN7 1/20 0.61
▸ HDAC9 Q9UKV0 1/20 0.61
▸ HDAC5 Q9UQL6 1/20 0.61
▸ POLB P06746 1/20 0.59
▸ EDNRA P25101 2/20 0.58
▸ GRM1 Q13255 2/20 0.57
▸ GRM2 Q14416 1/20 0.57
▸ GRM4 Q14833 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ GAA P10253 2/20 0.53
▸ EDNRB P24530 1/20 0.52
▸ FABP7 O15540 4/20 0.52
▸ FABP5 Q01469 4/20 0.52
▸ FABP3 P05413 3/20 0.50
▸ P4HB P07237 1/20 0.50
▸ HTT P42858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12499597 0.95 POLB (0.64) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL1029251 0.95 POLB (0.64) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL30788903 0.95 POLB (0.64) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL12694388 0.95 POLB (0.64) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL8643008 0.95 POLB (0.64) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL12499594 0.95 POLB (0.64) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL8932091 0.92 POLB (0.62) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL20614651 0.90 POLB (0.70) POLBEDNRAGRM1GRM2GRM4
SCHEMBL4560501 0.90 POLB (0.70) POLBEDNRAGRM1GRM2GRM4
SCHEMBL21120223 0.90 POLB (0.70) POLBEDNRAGRM1GRM2GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108778569-B Method for obtaining nano-copper particles and use of these particles 智利大学 2021-10-29 — — CN claimed
EP-3398700-A1 METHOD FOR PRODUCING COPPER NANOPARTICLES AND USE OF SAID PARTICLES Universidad de Chile (CL) 2018-11-07 — — EP claimed
US-20180297121-A1 METHOD FOR PRODUCING COPPER NANOPARTICLES AND USE OF SAID PARTICLES UNIVERSIDAD DE CHILE (CL) 2018-10-18 — — US claimed
WO-2026100662-A1 LIQUID CRYSTAL ALIGNING AGENT AND LIQUID CRYSTAL DISPLAY ELEMENT 日産化学株式会社 2026-05-15 — — WO disclosed
US-20250348000-A1 RESIST UNDERLAYER FILM-FORMING COMPOSITION NISSAN CHEMICAL CORPORATION (JP) 2025-11-13 — — US disclosed
EP-3452441-B1 ALPHA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF UNIV NEW YORK STATE RES FOUND (US) 2025-08-27 — — EP disclosed
US-20250155813-A1 PROTECTIVE FILM FORMING COMPOSITION NISSAN CHEMICAL CORPORATION (JP) 2025-05-15 — — US disclosed
CN-119856108-A Liquid crystal aligning agent and liquid crystal display element 日产化学株式会社 2025-04-18 — — CN disclosed
WO-2025047698-A1 PHOTOSENSITIVE COMPOSITION, CURED PRODUCT, METHOD FOR PRODUCING SAME, LIQUID CRYSTAL DEVICE, SEMICONDUCTOR DEVICE, POLYMER, AND COMPOUND JSR株式会社 2025-03-06 — — WO disclosed
WO-2025033304-A1 METHOD FOR MANUFACTURING LIQUID CRYSTAL ALIGNMENT FILM, AND METHOD FOR MANUFACTURING LIQUID CRYSTAL DISPLAY ELEMENT 日産化学株式会社 2025-02-13 — — WO disclosed
CN-119301526-A Composition for forming resist underlayer film 日产化学株式会社 2025-01-10 — — CN disclosed
US-20060204192-A1 Optical waveguide using polymer composed of silsesquioxane derivative JNC CORPORATION (JP) 2006-09-14 — — US disclosed
US-6949281-B1 Varnish composition and liquid-crystal display element CHISSO CORPORATION (JP) 2005-09-27 — — US disclosed
US-20050009982-A1 Compound having silsesquioxane skeleton and its polymer CHISSO CORPORATION (JP) 2005-01-13 — — US disclosed
US-6569600-B2 Optical apparatus comprising binders, sensitizers and reactants capable of undergoing rearrangements when exposed to actinic radiation causing optical changes such as refractive index EASTMAN KODAK COMPANY 2003-05-27 — — US disclosed
US-20030072250-A1 When exposed to actinic radiation produces a change in optical properties in the exposed region, contains a binder, a reactant capable of undergoing a transformation upon an electrone oxidation, and a sensitizer EASTMAN KODAK COMPANY 2003-04-17 — — US disclosed
EP-1246179-A2 Optical recording material EASTMAN KODAK COMPANY (US) 2002-10-02 — — EP disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
WO-2000063140-A1 TEMPLATE DIRECTED SOLID-STATE ORGANIC SYNTHESIS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2000-10-26 — — WO disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009982-A1 Compound having silsesquioxane skeleton and its polymer C1S, H1-4, H1-0 HDAC4 362/4885HDAC3 595/4885HDAC7 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback